MicroTech Medical’s US$249 Million Initial Public Offering

Davis Polk advised MicroTech Medical, while Clifford Chance has advised the joint sponsors involved in the transaction.

The Hangzhou-based firm offers diabetes therapy and manufactures medical devices to improve diabetes management globally. Besides its home country, MicroTech Medical’s flagship product – the equal patch insulin pump system (Equil) – is sold to over 20 countries across Europe, Asia Pacific, the Middle East, Africa and Latin America.

Goldman Sachs and China International Capital Corporation acted as Joint Sponsors.

The Clifford Chance team was jointly led by partners Fang Liu (Picture) and Virginia Lee, supported by counsel Chen Sheng, associates Chen Hongzhou, Jiao Luyi, Fan Yumeng and Yang Tao.

The Davis Polk corporate team included partners Yang Chu and Xuelin (Steve) Wang, counsel Lillian Lian, associates Sarah Shi and Jeffrey Lee and registered foreign lawyer Jerry Wu. Counsel Alon Gurfinkel and associate Omer Harel provided tax advice. Associate Sijia Cai provided 1940 Act advice. 

Involved fees earner: Liu Fang – Clifford Chance; Virginia Lee – Clifford Chance; Chen Sheng – Clifford Chance; Tao Yang – Clifford Chance; Yang Chu – Davis Polk & Wardwell; Alon Gurfinkel – Davis Polk & Wardwell; Omer Harel – Davis Polk & Wardwell; Jeffrey Lee – Davis Polk & Wardwell; Lillian Lian – Davis Polk & Wardwell; Sarah Shi – Davis Polk & Wardwell; Sijia Cai – Davis Polk & Wardwell; Xuelin Wang – Davis Polk & Wardwell; Jerry Wu – Davis Polk & Wardwell;

Law Firms: Clifford Chance; Davis Polk & Wardwell;

Clients: China International Capital Corporation Limited (CICC); Goldman Sachs; MicroTech Medical;

Author: Giulia Di Palma